Last updated: September 6, 2026
FLOLIPID is a prescription simvastatin oral suspension supplied at 20 mg per 5 mL. Its excipient system supports suspension uniformity, palatability, preservation, and dose administration for patients who cannot use conventional tablets. The commercial opportunity is concentrated in pediatric heterozygous familial hypercholesterolemia, dysphagia, enteral-tube administration, and differentiated liquid formulations rather than broad substitution of low-cost simvastatin tablets.
The principal excipients identified in the FDA product labeling are sucrose, glycerin, xanthan gum, polysorbate 80, sodium benzoate, citric acid, flavoring, and purified water.[1] These materials create a conventional aqueous suspension platform, but they also define the product’s main formulation vulnerabilities: sugar content, preservative dependence, taste, physical stability, dosing accuracy, and handling after opening.
What is FLOLIPID and how is it positioned commercially?
FLOLIPID is an oral suspension containing simvastatin, an HMG-CoA reductase inhibitor. The labeled concentration is 20 mg per 5 mL, equivalent to 4 mg/mL.[1]
| Product attribute |
FLOLIPID |
| Active ingredient |
Simvastatin |
| Dosage form |
Oral suspension |
| Strength |
20 mg/5 mL |
| Concentration |
4 mg/mL |
| Therapeutic class |
HMG-CoA reductase inhibitor |
| Primary indications |
Hyperlipidemia and cardiovascular risk reduction |
| Pediatric use |
Heterozygous familial hypercholesterolemia in patients 10 to 17 years old, subject to labeling limitations |
| Administration |
Oral dosing using a calibrated measuring device |
| Regulatory pathway |
FDA-approved new drug application |
| Commercial differentiation |
Liquid delivery, dose flexibility, and use in patients unable to swallow tablets |
Simvastatin tablets are widely available as low-cost generic products. FLOLIPID therefore competes on dosage form and patient access rather than molecule-level novelty. Its addressable market includes patients with swallowing difficulty, pediatric patients, individuals requiring non-tablet dosage forms, and caregivers who need flexible dose measurement.
What excipients are used in FLOLIPID?
The FLOLIPID formulation uses a multi-function excipient system.[1]
| Excipient |
Likely formulation role |
Commercial and regulatory relevance |
| Sucrose |
Sweetener, viscosity and mouthfeel contributor |
Improves palatability but limits suitability for sugar-restricted patients |
| Glycerin |
Co-solvent, humectant, sweetness and mouthfeel modifier |
Supports sensory quality and liquid-body characteristics |
| Xanthan gum |
Suspending and viscosity-enhancing agent |
Helps maintain dose uniformity during storage |
| Polysorbate 80 |
Wetting and dispersing agent |
Supports dispersion of hydrophobic simvastatin |
| Sodium benzoate |
Antimicrobial preservative |
Helps control microbial growth in a multidose aqueous product |
| Citric acid |
pH adjustment and flavor support |
Influences chemical stability, taste, and preservative performance |
| Flavoring |
Taste masking |
Important for pediatric acceptance and adherence |
| Purified water |
Continuous aqueous phase |
Determines suspension behavior, microbial risk, and packaging needs |
Simvastatin is poorly water-soluble. FLOLIPID is therefore a suspension rather than a true aqueous solution. The formulation must keep simvastatin particles adequately dispersed, allow reproducible redispersion after settling, and deliver the labeled dose after shaking.
How does the FLOLIPID excipient system work?
Suspension stability
Xanthan gum increases the viscosity of the aqueous vehicle and reduces the rate at which simvastatin particles settle. The system must remain pourable while providing enough structure to limit rapid sedimentation.
Polysorbate 80 improves wetting of hydrophobic simvastatin particles. Without effective wetting, particles may float, agglomerate, or resist uniform redistribution. Excess surfactant, however, can affect taste, foaming, interfacial behavior, and chemical stability.
The formulation’s practical performance depends on more than sedimentation rate. A commercial suspension must also show:
- Rapid and reproducible redispersion.
- Low risk of hard-cake formation.
- Consistent dose delivery at the beginning, middle, and end of the bottle.
- Acceptable viscosity for children and caregivers.
- Compatibility with the dosing syringe or cup.
- Physical stability through the labeled shelf life.
Palatability
Sucrose, glycerin, and flavoring address simvastatin’s sensory profile. Pediatric statin therapy can require long-term use, making taste and swallowability important commercial attributes.
Taste masking must account for the active ingredient, preservative, surfactant, and acidic pH. A flavor that performs well in a laboratory screening may perform poorly after storage because of flavor loss, oxidation, adsorption to packaging, or changes in suspension structure.
A competitive formulation could improve the sensory profile by using:
- Lower bitter-exposure through particle coating.
- Ion-exchange resin complexes.
- Polymer-based microencapsulation.
- Alternative flavor systems.
- A smaller dose volume through higher concentration.
- Sugar-free sweetening systems.
Each change would require compatibility, stability, dose-uniformity, and pediatric acceptability data.
Microbial control
Sodium benzoate provides antimicrobial protection in the multidose aqueous product. Its effectiveness depends on pH, concentration, microbial challenge performance, container closure, and in-use handling.
The preservative system creates several development requirements:
- Preservative effectiveness testing.
- Container-closure integrity.
- Microbial limits testing.
- In-use stability after repeated opening.
- Compatibility with dosing devices.
- Assessment of preservative migration or adsorption.
A preservative-free version could have commercial value, but it would likely require a single-dose presentation, a sterile or aseptically controlled process, a dry-powder format, or a validated packaging system that materially reduces contamination risk.
What formulation opportunities exist for FLOLIPID?
Sugar-free simvastatin suspension
The labeled use of sucrose creates a direct opportunity for a sugar-free product. A sugar-free formulation could target patients with diabetes, obesity-related metabolic disease, dental concerns, or caregiver preference for reduced sugar exposure.
Potential sweetener systems include sucralose, acesulfame potassium, saccharin, or polyol-based combinations. The replacement cannot be evaluated only on sweetness. The formulation team would need to assess:
- Bitterness suppression.
- Aftertaste.
- Osmolality.
- Viscosity.
- Preservative performance.
- Pediatric acceptance.
- Chemical stability.
- Labeling implications.
A sugar-free product would have the clearest commercial differentiation if supported by a superior taste profile and a convenient dosing device.
Higher-concentration liquid
FLOLIPID provides 20 mg in 5 mL. A higher-concentration formulation could reduce administration volume for patients receiving larger doses. The main technical risk is increased particle loading, which can raise viscosity, settling, aggregation, and dose nonuniformity.
A 10 mg/mL formulation, for example, could reduce the volume by half, but it would require new development work around:
- Suspension rheology.
- Redispersion.
- Syringe accuracy.
- Dose withdrawal from the container.
- Taste intensity.
- Sedimentation behavior.
- Labeling and dosing-error prevention.
Higher concentration can increase medication-error risk if the new strength is confused with the existing 4 mg/mL product. Distinct packaging and dosing instructions would be necessary.
Unit-dose and stick-pack formats
Unit-dose packaging could reduce contamination and simplify administration in hospitals, long-term care, schools, and home settings. It could also support preservative reduction or elimination.
Relevant formats include:
- Premeasured oral syringes.
- Single-dose cups.
- Sachets or stick packs.
- Small-volume bottles with calibrated adapters.
- Blistered liquid-dose systems.
The commercial tradeoff is higher packaging cost and more complex manufacturing. Unit-dose formats have the strongest economic rationale where dosing accuracy, infection control, and nursing efficiency matter.
Enteral-tube-compatible formulation
Patients with feeding tubes may represent a targeted use case. A tube-compatible FLOLIPID formulation would require testing for:
- Delivery through common tube sizes.
- Adsorption to tubing.
- Flush-volume requirements.
- Clogging risk.
- Recovery of simvastatin dose.
- Compatibility with enteral nutrition.
- Administration-site instructions.
The current label does not establish a separate enteral-tube indication. A manufacturer making explicit tube-administration claims would need supporting regulatory documentation.
What FDA regulatory issues affect excipient changes?
A change to the excipient system could range from a post-approval supplement to a new product development program, depending on the extent of the change and its effect on product performance.
Key regulatory studies would include:
| Development area |
Core evidence |
| Physical stability |
Sedimentation, redispersion, particle-size distribution, viscosity |
| Chemical stability |
Assay, degradation products, pH, preservative content |
| Microbiology |
Microbial limits and preservative effectiveness |
| Dose uniformity |
Beginning, middle, and end of container testing |
| Container closure |
Extractables, leachables, compatibility, integrity |
| In-use performance |
Repeated opening, storage, shake instructions, dosing accuracy |
| Clinical bridging |
Needed when formulation changes may affect exposure or tolerability |
| Human factors |
Device usability and dosing-error assessment |
| Pediatric acceptability |
Taste and swallowability assessment where relevant |
The FDA’s inactive-ingredient framework permits broad use of established excipients, but the regulatory acceptability of a specific combination depends on route, dosage form, quantity, patient population, and precedent in approved products.[2]
How strong is the commercial protection for an excipient-based FLOLIPID strategy?
The main commercial protection would likely come from formulation differentiation, regulatory execution, trademarks, manufacturing know-how, and device integration rather than broad protection for simvastatin itself.
Potential intellectual-property claims could cover:
- Specific excipient ratios.
- Particle-size distributions.
- Coated or encapsulated simvastatin particles.
- Sugar-free taste-masking systems.
- High-concentration suspensions.
- Preservative-free packaging.
- Dosing-device and bottle-adapter combinations.
- Stability profiles under defined storage conditions.
- Manufacturing processes that produce improved redispersion or content uniformity.
A formulation patent is strongest when it links a narrow composition to a measurable technical result, such as improved dose uniformity, reduced sedimentation, lower bitterness, or enhanced stability. Broad claims covering ordinary use of xanthan gum, glycerin, polysorbate 80, or sodium benzoate would face substantial prior-art risk because these excipients are widely used in oral liquids.
Trade-secret protection may be more practical for:
- Flavor blends.
- Mixing order.
- Hydration conditions for xanthan gum.
- Particle-size control.
- Deaeration procedures.
- Filling parameters.
- In-process suspension controls.
What generic and competitive risks affect FLOLIPID?
The molecule is exposed to extensive generic competition because simvastatin tablets are widely available. The liquid dosage form has a narrower competitor set, but substitution pressure remains significant.
| Competitive threat |
Impact on FLOLIPID |
| Generic simvastatin tablets |
Limits pricing power and encourages tablet substitution |
| Compounded simvastatin liquids |
Can compete in local markets but may have variable quality and limited commercial scale |
| Alternative statins |
Atorvastatin and rosuvastatin offer competing efficacy, dosing, and formulation options |
| Other liquid statins |
Could capture pediatric and dysphagia patients if available |
| Pharmacy dose manipulation |
May reduce demand for branded liquid product |
| New oral liquid platforms |
Could offer improved taste, dosing, or sugar-free positioning |
FLOLIPID’s defensible market is the segment where a validated, commercially manufactured liquid is preferred over tablet swallowing, extemporaneous compounding, or dose manipulation.
How does FLOLIPID compare with tablet simvastatin?
| Factor |
FLOLIPID |
Simvastatin tablets |
| Swallowing burden |
Low |
Higher |
| Dose flexibility |
High |
Limited by tablet strengths |
| Pediatric administration |
More practical |
Less practical |
| Stability complexity |
High |
Lower |
| Packaging requirements |
More demanding |
Conventional solid-dose packaging |
| Microbial risk |
Requires control |
Minimal compared with aqueous liquid |
| Cost of goods |
Higher |
Lower |
| Taste risk |
Significant |
Limited after swallowing |
| Tube-administration potential |
Testable but formulation-specific |
Requires crushing or alternative handling |
| Price competition |
Indirect and dosage-form based |
Intense generic competition |
What are the highest-value commercial opportunities?
The strongest opportunities are:
- A sugar-free, well-tolerated pediatric suspension.
- A higher-concentration product that reduces administration volume.
- A calibrated oral-syringe presentation with dose-error controls.
- A unit-dose or preservative-reduced format for institutional use.
- An enteral-tube-compatible product supported by validated administration data.
- A premium formulation with improved taste and longer in-use stability.
- A co-branded or licensed product for specialty pharmacies and pediatric lipid clinics.
The business case is strongest when the formulation improvement solves a documented administration problem and supports a differentiated regulatory claim. A simple excipient substitution without superior taste, stability, convenience, or safety is unlikely to overcome the price advantage of generic simvastatin tablets.
Key Takeaways
- FLOLIPID is a 4 mg/mL simvastatin oral suspension.
- Its listed excipients support sweetness, wetting, suspension stability, preservation, pH control, and flavor.
- The current formulation’s principal vulnerabilities are sucrose content, taste, multidose microbial control, and suspension-dose uniformity.
- Sugar-free, higher-concentration, unit-dose, and enteral-tube-compatible products offer the clearest commercial development paths.
- Excipient patents would need narrow composition or performance claims because the individual excipients are well established.
- Generic tablets constrain pricing, so commercial value depends on liquid-delivery advantages.
- Device integration and validated dosing performance can provide stronger differentiation than excipient changes alone.
- FDA regulatory work will center on stability, preservative effectiveness, dose uniformity, packaging compatibility, and human factors.
FAQs
Is FLOLIPID a solution or a suspension?
FLOLIPID is an oral suspension. Simvastatin is dispersed as particles in an aqueous vehicle rather than fully dissolved.
Does FLOLIPID contain sugar?
Yes. The FDA labeling identifies sucrose as an inactive ingredient.[1]
Can FLOLIPID be reformulated without sodium benzoate?
Potentially, but a preservative-free multidose liquid would require a different microbial-control strategy, such as single-dose packaging or a validated alternative preservation approach.
Why is xanthan gum used in FLOLIPID?
Xanthan gum increases vehicle viscosity and helps maintain suspension uniformity during storage and dosing.
Can a higher-strength FLOLIPID formulation be marketed as a line extension?
A higher-strength liquid would require formulation, stability, dose-uniformity, packaging, labeling, and regulatory evaluation. It would not be an automatic extension of the existing 20 mg/5 mL product.
References
- U.S. Food and Drug Administration. (n.d.). FLOLIPID (simvastatin) oral suspension prescribing information. DailyMed.
- U.S. Food and Drug Administration. (2016). Inactive ingredient database. Center for Drug Evaluation and Research.
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Orange Book.
- U.S. Food and Drug Administration. (2015). Questions and answers on quality considerations for chewable tablets. Center for Drug Evaluation and Research.
